October 03, 2014

Today's Top Alzheimer's News

Rep. Andy Harris (R-MD) calls on NIH to focus dollars on younger researchers working in areas like Alzheimer's, John Palmer donates $1 million to University of Mississippi MIND Center, and the latest breakthrough in Beta amyloid research (read more). 
 

Must reads

  • An October 2, 2014 New York Times opinion piece by Representative Andy Harris (R-MD) called for better utilization of NIH funds to support younger researchers working in priority areas like Alzheimer's. According to Rep. Harris, "A study for the National Bureau of Economic Research from 2005 examined the age at which over 2,000 Nobel Prize winners and other notable scientists in the 20th century came up with the idea that led to their breakthrough. Most were between 35 and 39. Yet the median age of first-time recipients of R01 grants, the most common and sought-after form of N.I.H. funding, is 42, while the median age of all recipients is 52. More people over 65 are funded with research grants than those under age 35…We’ll never know what breakthroughs were missed because young investigators were not provided with the resources necessary to pursue unique ideas over the last 15 years. They may have had the idea that would have led to a cure for ovarian cancer, Alzheimer’s disease or pediatric cardiomyopathy…The federal government, through the N.I.H., is and should remain a vital source of funding for cutting-edge research. But for that very reason, it’s not enough to throw money at researchers, especially when it goes to people who, though well-regarded in their fields, are past the age when they are most likely to make a significant contribution to science. Doing a better job of targeting good researchers who are doing valuable work in the prime of their careers can ensure that taxpayer money is well spent, and that science as a whole continues to benefit us all."
  • An October 2, 2014 The Clarion-Ledger (MS) article reported that "Jackson businessman John N. Palmer, whose wife and [mother-in-law] both succumbed to Alzheimer’s several years ago, has donated $1 million to the MIND Center, a University of Mississippi Medical Center institution dedicated to fighting the disease." According to the article, "The gift from the telecommunications pioneer and former U.S. ambassador to Portugal pushed donations to the Memory Impairment and Neurodegenerative Dementia Research Center above the $10 million mark — a goal set in 2010, the year it opened at UMMC."
Research, science, and technology
  • An October 3, 2014 MedCity News article reported that Massachusetts startup Cognoptix is "developing a quick, in-office eye test for the early diagnosis of Alzheimer’s disease." According to the article, "Cognoptix has raised more than $15 million in a Series D round, the company says, to test its test in late-stage clinical trials. Cognoptix’s optical scanning machine, called the Sapphire II, can detect beta amyloid in a person’s eyes. Beta amyloid is a substance that builds up in the brains of patients with Alzheimer’s; it also aggregates in the lens, and its levels can be monitored non-invasively by a primary care physician with the simple eye test. The doctor just drops a beta amyloid-specific fluorescent dye into the patient’s eyes, and the likelihood of his or her having the disease is spun out of the machine."
  • An October 2, 2014 Genetic Engineering & Biotechnology News article reported that scientists based at the Institute for Research in Biomedicine have linked beta amyloid aggregates of intermediate size to Alzheimer's disease. According to the article, "Beta amyloid, the peptide long associated with Alzheimer’s disease, embodies a diabolical version of the Goldilocks principle. For beta amyloid, “just right,” when it comes to killing neurons, means forming aggregates of intermediate size—specifically, aggregates of 20 to 100 units. Neither smaller aggregates nor amyloid fibrils, which can contain up to 3,000 peptide units, are as toxic.This finding, from scientists based at the Institute for Research in Biomedicine (IRB Barcelona), squarely faces one of the key uncertainties in Alzheimer’s research, namely, the lack of unequivocal proof that beta amyloid causes the onset and development of the disease. Beta amyloid in isolation is not harmful. And, while beta amyloid aggregates are associated with Alzheimer’s, it has been unclear which aggregates might actually be harmful…By characterizing the shifting patterns of beta amyloid structures, the researchers hope to advance the search for and design of therapeutic molecules."